You cannot audit a confident guess
In regulated environments, the biggest GenAI failure mode is not a typo. It is a plausible-sounding answer with no verifiable basis. The fix is to define a “no hallucinations” contract: rules the assistant must follow so outputs remain defensible.
Define the contract in five rules
Rule 1: Cite sources or refuse. If the assistant cannot point to an approved source, it must say it cannot answer within scope.
Rule 2: Separate facts from suggestions. Output should label what is directly supported by sources versus what is a proposed next step.
Rule 3: Never invent references. No fake SOP titles, no made-up section numbers, no fictional guidance.
Rule 4: Confirm effective versions. When using controlled documents, the assistant should reference the effective date or version.
Rule 5: Route high-risk topics to human review. If output could influence a GxP decision, it must require documented review.
How to validate the contract
Use a fixed test pack: correct citations, missing source cases, contradictory sources, and out-of-scope prompts. Store results with prompt and model versions.
This contract turns GenAI from “creative” into controlled, which is what pharma actually needs.
In recent years, validation processes across the pharmaceutical industry have been undergoing a major transformation. Workflows that were traditionally managed through paper documentation, spreadsheets and manual review cycles are increasingly moving toward digital validation platforms. As a result, life sciences organizations often evaluate solutions such as Kneat, Validfor, ValGenesis, MasterControl and Veeva when modernizing validation lifecycle management and compliance documentation.